Business Context and Reporting Period
Company: Eni S.p.A.
Filing Type: Form 6-K (Interim Consolidated Report)
Reporting Period: First half of 2025 (ended June 30, 2025)
Filing Date: August 6, 2025
Eni is an integrated energy company focused on a just energy transition. The reporting period covers the first six months of 2025, characterized by a challenging commodity price environment (Brent down 15% vs. prior year) and a strengthening Euro. The company continues to execute its strategy of portfolio optimization, divesting non-core assets, and investing in transition businesses (renewables, biofuels, CCUS).
Key Financial Metrics
| Metric | First Half 2025 | First Half 2024 | Change |
|---|---|---|---|
| Sales from Operations | €41,332 million | €44,651 million | -7.4% |
| Operating Profit | €3,490 million | €4,251 million | -17.9% |
| Proforma Adjusted EBIT | €6,362 million | €8,223 million | -22.6% |
| Net Profit (Attributable to Eni) | €1,715 million | €1,872 million | -8.4% |
| Adjusted Net Profit (Attributable to Eni) | €2,546 million | €3,101 million | -17.9% |
| Net Cash Flow from Operating Activities | €5,902 million | €6,475 million | -8.9% |
| Capital Expenditure | €3,773 million | €3,952 million | -4.5% |
| Net Borrowings (ex-IFRS 16) | €10,198 million | €12,113 million | -15.8% |
| Leverage (ex-IFRS 16) | 19% | 22% | -3 ppts |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased by €3.3 billion, primarily driven by a 15% drop in Brent crude prices and lower refining margins. Natural gas sales volumes also declined by 15% due to lower marketing volumes in Italy and Europe.
- Segment Performance:
- Exploration & Production (E&P): Proforma adjusted EBIT fell 18% to €5.73 billion due to lower realizations, partially offset by volume growth and cost efficiencies.
- Global Gas & Power: Proforma adjusted EBIT rose 21% to €0.86 billion, supported by gas portfolio value maximization and favorable settlements.
- Refining & Chemicals: Reported a proforma adjusted loss of €0.53 billion (worsening from €0.25 billion loss in 2024) due to weak European demand and adverse market conditions.
- Transition Businesses: Enilive EBIT dropped 28% due to deteriorated bio margins; Plenitude EBIT was down 4% due to weaker retail results, though renewable capacity grew 45% year-over-year.
- Balance Sheet: Net borrowings decreased by approximately €2 billion. Shareholders' equity decreased by €2.2 billion, largely due to negative currency translation differences and shareholder remuneration, partially offset by gains from the sale of minority interests in Enilive and Plenitude.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Flow: Eni raised its full-year 2025 Cash Flow From Operations (CFFO) outlook to circa €11.5 billion (before working capital adjustments), an improvement of €0.5 billion over the original plan.
- Capex: Full-year gross capex is expected to be below €8.5 billion (reduced from initial guidance of below €9 billion).
- Production: Oil and gas production is expected to remain at 1.7 million boe/d for the full year.
- Shareholder Returns: Confirmed a 5% dividend increase to €1.05 per share for 2025. A new share buy-back program of at least €1.5 billion (potentially up to €3.5 billion) was launched, with €440 million executed as of July 18, 2025.
- Leverage: Year-end leverage is expected to be between 0.15 and 0.20 on a proforma basis.
Risks and Contingencies
- Commodity Volatility: Significant exposure to oil and gas price fluctuations. The company revised its 2025 Brent forecast down to $70/bbl.
- Geopolitical Risks: Exposure to instability in Libya, Egypt, and Venezuela. Eni has significant overdue receivables from state-owned companies in Egypt and Venezuela (PDVSA), though a repayment plan is in place for Egypt.
- Regulatory & Legal: Ongoing antitrust proceedings in Italy regarding bio-component pricing and alleged abuse of dominant position in bioplastics (Novamont). A fine of €32 million was imposed by the Italian Antitrust Authority in June 2025, with Eni contesting the decision.
- Energy Transition: Risks related to the structural decline in hydrocarbon demand and the feasibility of decarbonization technologies.
Investor Verification Checklist
- Dividend & Buyback Execution: Verify the timing and execution of the new €1.5 billion buy-back program and the four quarterly dividend tranches totaling €1.05 per share.
- Transition Business Valuation: Monitor the completion of the 20% stake sale in Plenitude to Ares Management (€2 billion) and the ongoing negotiations for the CCUS business spin-off with Global Infrastructure Partners (GIP).
- Refining Restructuring: Track the progress of the Livorno biorefinery conversion and the closure of unprofitable cracking units in Brindisi and Priolo.
- Receivables Recovery: Assess the collection status of overdue receivables from Egyptian and Venezuelan state-owned entities.
- Antitrust Litigation: Follow the outcome of the Italian Antitrust Authority (AGCM) proceedings regarding bio-component pricing and the Novamont bioplastics case.